In a patient with decompensated liver disease and a prior history of type 2 diabetes mellitus who has an elevated C‑peptide level, what is the likelihood that the diabetes is autoimmune (type 1)?

Likelihood of Autoimmune Diabetes with C-peptide 6.7

In a patient with decompensated liver disease and prior type 2 diabetes who has a C-peptide of 6.7 (ng/mL), autoimmune diabetes is extremely unlikely—this elevated C-peptide essentially rules out latent autoimmune diabetes in adults (LADA) or type 1 diabetes.

Interpretation of C-peptide Level

Your patient's C-peptide of 6.7 ng/mL is significantly elevated above the normal range (0.8-5.2 ng/mL). This finding is incompatible with autoimmune diabetes for the following reasons:

• Autoimmune diabetes destroys pancreatic β-cells, resulting in low or undetectable C-peptide levels 1
• Research specifically examining LADA screening found that only 1 out of 39 LADA patients had C-peptide above normal range, while all type 2 diabetes patients had normal or elevated levels 2
• Elevated C-peptide effectively rules out LADA and eliminates the need for expensive anti-GAD antibody testing 2

Clinical Context: Decompensated Liver Disease

The elevated C-peptide in your patient is likely explained by:

• Hepatic insulin resistance associated with liver disease, which drives compensatory hyperinsulinemia and elevated C-peptide
• Studies in LADA patients with fatty liver disease show that higher C-peptide levels correlate with more severe insulin resistance and metabolic dysfunction 3
• The liver disease itself creates a metabolic milieu that increases insulin resistance, further elevating C-peptide production

When to Consider Autoimmune Diabetes

Autoimmune diabetes should be suspected when 1, 4:

• C-peptide is low or low-normal (not elevated)
• Rapid deterioration of glycemic control despite appropriate therapy
• Younger age at onset, lean body habitus
• Personal or family history of autoimmune conditions

A critical pitfall: When C-peptide is "low-normal" (e.g., 1.3 ng/mL in a recent case), autoantibody testing should still be pursued, as this can represent early β-cell failure 5. However, your patient's C-peptide of 6.7 is far above this threshold.

Autoantibody Testing Not Indicated

While 10-15% of clinically diagnosed type 2 diabetes patients have detectable islet autoantibodies 6, 4, testing is not warranted in your patient because:

• The elevated C-peptide demonstrates preserved (actually excessive) β-cell function
• Autoantibody testing should be reserved for patients with low or normal C-peptide 2
• The presence of decompensated liver disease provides an alternative explanation for metabolic derangement

Likelihood Assessment

The likelihood of autoimmune diabetes in your patient is <1% based on the elevated C-peptide alone. The combination of:

• C-peptide 6.7 (markedly elevated)
• Prior diagnosis of type 2 diabetes
• Decompensated liver disease (causing insulin resistance)

...creates a clinical picture entirely consistent with type 2 diabetes with hepatic insulin resistance, not autoimmune diabetes.

1, 2